Nature Medicine
@NatureMedicine
Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians.
Congrats to R. Loos, J. Hirschhorn, & colleagues developing a new polygenic risk score for obesity. Very interesting that it predicts response with weight loss across 2 lifestyle intervention RCTs nature.com/articles/s4159… @NatureMedicine My comments in @nytimes…
Read about the scientific and technological breakthroughs reshaping transplant medicine - including the transformative role of AI, xenotransplantation and tissue engineering, and novel approaches to immunosuppression. nature.com/articles/s4159…
When tested in a multiethnic cohort of ~2.5 million US veterans, the PREVENT equations, recently developed by the American Heart Association for sex-specific and race-free prediction of cardiovascular disease risk, were shown to accurately estimate this risk with some…
In a phase 1b trial in 3 patients with Fanconi anemia, an irradiation and busulfan-free conditioning regimen containing an anti-CD117 antibody, combined with T- and B-cell depleted haploidentical hematopoietic stem cell transplant, was safe and led to high levels of engraftment.…
A combination of animal studies, data from a clinical trial, and insights from an observational cohort suggest that, in individuals with MASH, semaglutide improves liver histology by reverting patient proteomes to better mimic the proteome of individuals without the disease.…
Polygenic scores for BMI and obesity constructed using data from 5M individuals with different ancestries were associated with distinct weight gain trajectories from early childhood to adulthood @novonordiskfond @IcahnMountSinai nature.com/articles/s4159…
ICYMI @BillGates wrote a World View for @NatureMedicine about how his father's death from Alzheimer's disease prompted him to support a global collaboration of top dementia researchers @_neuroproteome to accelerate proteomics discovery. Read Gates here: ow.ly/sFtf50WsN04…
Preliminary results from a phase 1/2 trial show that an AAV-OTOF gene therapy is safe and leads to hearing improvements in 10 patients with congenital #deafness with 6-12 months follow up, including a teenager and a young adult, expanding the age range from previous trials.…
Our latest Review summarizes the current knowledge on mortality-defining toxicities of #CARTcell therapies, beyond CRS and ICANS. @KRejeski & colleagues discuss underlying mechanisms of rare and long-term toxicities and how these affect timing and management, and outline key…
In a silent trial involving 197 lung cancer patients over the span of four months, a pathology foundation model was able to identify presence of EGFR mutations with high accuracy, potentially preventing further genetic testing in 43% of cases. nature.com/articles/s4159…
#StemCell therapies for #diabetes have entered the clinic; our latest Review summarizes the advances that got us here, lessons learned from early trials & the clinical, manufacturing & regulatory challenges that must now be overcome nature.com/articles/s4159…
An explosion of #digitaltools and #AI is catalyzing innovations in the mission to scale up #mentalhealth support worldwide. These paradigms currently rely on a ‘human in the loop’ — but who is the human in question, and does it matter? News & Views from Anushka Patel and Ernesto…
In this multicenter phase 1 trial, patients with advanced gastric and gastroesophageal junction cancer were safely treated with the CLDN18.2- targeting antibody drug conjugate SHR-A1904, leading to encouraging objective response rates. #antibodydrugconjugate…
In this phase 1 trial, treatment with IBI343, a CLDN18.2- targeting antibody drug conjugate, was safe and showed encouraging clinical responses in patients with advanced gastroesophageal junction adenocarcinoma. @JiaJennyLiu #antibodydrugconjugate nature.com/articles/s4159…
In a prospective study including 2,300 pediatric and adult patients with liquid and solid tumors, RNA sequencing provided actionable molecular information in 87% of cases, including for diagnostic and therapy matching purposes. @CHawkinsLab nature.com/articles/s4159…
When tested in a multiethnic cohort of ~2.5 million US veterans, the PREVENT equations, recently developed by the American Heart Association for sex-specific and race-free prediction of cardiovascular disease risk, were shown to accurately estimate this risk with some…
Preliminary results from a phase 1/2 trial show that an AAV-OTOF gene therapy is safe and leads to hearing improvements in 10 patients with congenital deafness with 6-12 months follow up, including a teenager and a young adult, expanding the age range from previous trials.…
In a silent trial involving 197 lung cancer patients over the span of four months, a pathology foundation model was able to identify presence of EGFR mutations with high accuracy, potentially preventing further genetic testing in 43% of cases. nature.com/articles/s4159…
In a phase 1 trial, treatment of individuals with mixed #hyperlipidemia with a monoclonal antibody targeting the angiopoietin-like protein 3/8 complex resulted in dose-dependent reductions in the levels of #triglycerides and low-density lipoprotein cholesterol, while increasing…